X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TREMFYA (guselkumab) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor for the treatment of adult patients living with active Psoriatic Arthritis.
Lead Product(s): Guselkumab
Therapeutic Area: Immunology Product Name: Tremfya
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Addex Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
TAR-200 monotherapy (gemcitabine intravesical drug delivery system) and cetrelimab monotherapy (intravenous anti-PD-1 mAb) is being evaluated for Bacillus Calmette-Guérin- unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for radical cystectomy.
Lead Product(s): Gemcitabine,Cetrelimab
Therapeutic Area: Oncology Product Name: TAR-200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2023
Details:
Akeega is a combination of niraparib, a highly selective poly (ADP ribose) polymerase (PARP) inhibitor and abiraterone acetate, an androgen biosynthesis inhibitor is being studied for adult patients with BRCA1/2 gene mutated metastatic castration resistant prostate cancer.
Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Akeega
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
Imbruvica (ibrutinib) is a small-molecule inhibitor of BTK, it was granted NICE approval in combination with venetoclax as first-line treatment option for chronic lymphocytic leukaemia.
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
The agreement leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders for the investigational compound, PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor.
Lead Product(s): PIPE-307
Therapeutic Area: Neurology Product Name: PIPE-307
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Pipeline Therapeutics
Deal Size: $1,100.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement April 17, 2023
Details:
Erleada® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Lead Product(s): Apalutamide
Therapeutic Area: Oncology Product Name: Erleada
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Rybrevant® (amivantamab-vmjw) extracellular domains of EGFR and MET which disrupts EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET.
Lead Product(s): Amivantamab-vmjw,Lazertinib,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Spravato® (esketamine) is the S-enantiomer of racemic ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Spravato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Tremfya (guselkumab) is a human monoclonal IgG1 lamda antibody that selectively binds to and inhibits its interaction with IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.
Lead Product(s): Guselkumab
Therapeutic Area: Dermatology Product Name: Tremfya
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
